ES2173910T3 - Anticuerpos humanizados dirigidos contra el antigeno a33. - Google Patents

Anticuerpos humanizados dirigidos contra el antigeno a33.

Info

Publication number
ES2173910T3
ES2173910T3 ES94902059T ES94902059T ES2173910T3 ES 2173910 T3 ES2173910 T3 ES 2173910T3 ES 94902059 T ES94902059 T ES 94902059T ES 94902059 T ES94902059 T ES 94902059T ES 2173910 T3 ES2173910 T3 ES 2173910T3
Authority
ES
Spain
Prior art keywords
directed against
humanized antibodies
antibodies directed
against antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902059T
Other languages
English (en)
Inventor
David John King
John Robert Adair
Raymond John Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929225853A external-priority patent/GB9225853D0/en
Priority claimed from GB939315249A external-priority patent/GB9315249D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of ES2173910T3 publication Critical patent/ES2173910T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN PROTEINAS DE UNION DEL ANTIGENO A33 PARA SU USO EN LA DIAGNOSIS O EL TRATAMIENTO DE TUMORES COLORRECTALES Y METASTASIS QUE SE DERIVAN DE LOS MISMOS. LA PROTEINA DE UNION PUEDE SER UN ANTICUERPO A33 HUMANIZADO, QUE INCLUYA MOLECULAS DE ANTICUERPO COMPLETAS, FRAGMENTOS DE LAS MISMAS, Y, ESPECIALMENTE, PROTEINAS MONOESPECIFICAS, MULTIVALENTES QUE COMPRENDAN DOS, TRES, CUATRO O MAS ANTICUERPOS O FRAGMENTOS DE LOS MISMOS UNIDOS ENTRE SI MEDIANTE UN AGENTE ENLAZADOR. PARA DIAGNOSIS O TERAPIAS EL ANTICUERPO A33 HUMANIZADO PUEDE UNIRSE A UNA MOLECULA PORTADORA.
ES94902059T 1992-12-10 1993-12-10 Anticuerpos humanizados dirigidos contra el antigeno a33. Expired - Lifetime ES2173910T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929225853A GB9225853D0 (en) 1992-12-10 1992-12-10 Antigen-binding proteins
GB939315249A GB9315249D0 (en) 1993-07-22 1993-07-22 Antigen-binding proteins

Publications (1)

Publication Number Publication Date
ES2173910T3 true ES2173910T3 (es) 2002-11-01

Family

ID=26302139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902059T Expired - Lifetime ES2173910T3 (es) 1992-12-10 1993-12-10 Anticuerpos humanizados dirigidos contra el antigeno a33.

Country Status (12)

Country Link
EP (1) EP0628077B1 (es)
JP (1) JPH07504334A (es)
AT (1) ATE214734T1 (es)
AU (1) AU675268B2 (es)
CA (1) CA2128544A1 (es)
DE (1) DE69331735T2 (es)
DK (1) DK0628077T3 (es)
ES (1) ES2173910T3 (es)
GB (1) GB2278357B (es)
NZ (1) NZ258618A (es)
PT (1) PT628077E (es)
WO (1) WO1994013805A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190640B1 (en) * 1985-04-19 2001-02-20 Ludwig Institute For Cancer Research Method for treating neoplasia using humanized antibodies which bind to antigen A33
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
GB9215541D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
GB9215540D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
CA2126819A1 (en) * 1993-07-09 1995-01-10 Richard P. Mccabe Kit and method for pretargeting
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5712369A (en) * 1995-08-24 1998-01-27 Ludwig Institute For Cancer Research Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein
WO1998041613A1 (en) * 1997-03-14 1998-09-24 Otten Gillis R Targeted cytolysis of cancer cells
AU1097301A (en) * 1999-10-22 2001-05-08 Scripps Research Institute, The Humanization of non-human, mammalian antibodies
ATE353913T1 (de) 2000-04-21 2007-03-15 Fuso Pharmaceutical Ind Neue collectine
EP1448780A4 (en) * 2001-10-15 2005-08-31 Immunomedics Inc DIRECTLY TARGETED BONDING PROTEINS
KR100918746B1 (ko) * 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
JP5372500B2 (ja) 2005-06-17 2013-12-18 トレラクス リクイデーティング トラスト Ｉｌｔ３結合分子およびその使用
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US11733235B2 (en) 2016-12-27 2023-08-22 Chugai Seiyaku Kabushiki Kaisha Method for evaluating immunogenicity of test substance
US11555072B2 (en) * 2017-09-23 2023-01-17 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
CN110540591A (zh) * 2019-08-09 2019-12-06 无锡傲锐东源生物科技有限公司 一种抗糖蛋白A33（Glycoprotein A33）单克隆抗体及其免疫检测应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds

Also Published As

Publication number Publication date
WO1994013805A1 (en) 1994-06-23
AU675268B2 (en) 1997-01-30
GB2278357B (en) 1997-03-05
ATE214734T1 (de) 2002-04-15
GB2278357A (en) 1994-11-30
JPH07504334A (ja) 1995-05-18
DE69331735T2 (de) 2002-09-26
DE69331735D1 (de) 2002-04-25
GB9415880D0 (en) 1994-09-28
EP0628077B1 (en) 2002-03-20
DK0628077T3 (da) 2002-07-01
EP0628077A1 (en) 1994-12-14
NZ258618A (en) 1997-02-24
PT628077E (pt) 2002-07-31
CA2128544A1 (en) 1994-06-23
AU5656894A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
NO954626D0 (no) Anti-EGFR-enkeltkjede-Fv-er og anti-EGFR-antistoffer
EP2287201A3 (en) RS7 antibodies
NO930440D0 (no) Tri- og tetravalente monospesifikke antigen-bindingsproteiner
NO984136D0 (no) Humanisert kimært antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl
FI973120A (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
PT712307E (pt) Metodos para controlo da populacao de celulas b
RU94045249A (ru) Мономерное антитело, способ получения антитела, димерный слитый белок, способ получения белка, набор конструкций
RU2004107695A (ru) Способы удаления амилоида с помощью анти-амилоидных антител
BR0311799A (pt) Anticorpo monoclonal hpam4
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
DK0502812T3 (da) Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor
RU94028282A (ru) Биспецифическое антитело, способ его получения, моноклональные антитела, фармацевтический препарат, фармацевтические наборы, способ удаления опухолевых клеток, применение биспецифического фрагмента антитела
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
ATE173740T1 (de) Antikoerper mit geaenderter zielrichtung
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
DE69227776D1 (de) Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden
WO2023196539A3 (en) Compositions and methods for treatment of cancer
WO2022212654A3 (en) Cross-reactive monoclonal antibodies against coronaviruses
NO930663L (no) Homokonjugerte immunglobuliner

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 628077

Country of ref document: ES